Overcoming Development And Manufacturing Challenges For Biologic Therapies

Whether rapidly scaling manufacturing capabilities, shortening supply chains, accelerating the availability of emerging therapies, or reducing the risk of a pharmaceutical shortage - the pharmaceutical manufacturing platform can make all the difference in the success or failure of a biologic therapy.

Flexible capacity and equipment trains, combined with an agile, collaborative approach can provide biopharma clients the ability to scale a biologic product up from pilot batch to clinical and commercial quantities – accelerating time to market.

A long track record of successful inspections by regulatory authorities and international clients highlights a robust quality assurance program, where regulatory affairs experts compile and review all of the necessary data and documentation for regulatory CMC submission, ensuring products comply with applicable regulations.

Northway Biotech and its team of more than 200 professionals are deeply invested in utilizing the latest science and technological innovation to provide the highest-quality service, flexibility and responsiveness.

Northway Biotech is a global end-to-end biopharmaceutical contract development and manufacturing organization established in 2004 with a biomanufacturing facility in the heart of Europe – Vilnius, Lithuania, and a recently opened biomanufacturing site in Waltham, Massachusetts - part of the booming biotech hub in the Greater Boston Area.